AbbVie will buy Aliada Therapeutics for $1.4 billion in cash, it said on Monday, gaining access to the privately held therapy developer's Alzheimer's disease candidate as the U.S. drugmaker increases ...
It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical ...
Beacon Hill Roll Call records local senators’ votes on the only roll call from the week of Oct. 21-25. There were no roll calls in the House last week. CLEAN ENERGY AND ...